Morepen Laboratories Limited (IN:MOREPENLAB)
:MOREPENLAB
Want to see IN:MOREPENLAB full AI Analyst Report?
MOREPENLAB Stock Chart & Stats
₹41.99
-₹1.18(-1.56%)
At close: 4:00 PM EST
₹41.99
-₹1.18(-1.56%)
Day’s Range― - ―
52-Week Range₹33.42 - ₹70.40
Previous CloseN/A
Volume3.34M
Average Volume (3M)88.30K
Market Cap
₹22.86B
Enterprise Value₹24.96B
Total Cash (Recent Filing)₹932.86M
Total Debt (Recent Filing)₹1.58B
Price to Earnings (P/E)20.5
Beta1.75
Next Earnings
May 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.49%
Share Statistics
EPS (TTM)0.50
Shares Outstanding547,953,700
10 Day Avg. Volume126,704
30 Day Avg. Volume88,304
Financial Highlights & Ratios
PEG Ratio1.32
Price to Book (P/B)2.29
Price to Sales (P/S)1.45
P/FCF Ratio-28.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectorySustained top-line growth (7.5% year-over-year) indicates expanding commercial traction across APIs and formulations. Over a 2-6 month horizon this growth supports scale advantages, higher absolute cash generation potential, and funds reinvestment in R&D or capacity expansion to entrench market position.
Low Leverage / Strong Capital StructureA very low debt-to-equity ratio and high equity ratio provide structural financial resilience. This durable strength reduces refinancing risk, preserves strategic optionality for capex or acquisitions, and supports consistent investment in manufacturing and compliance without heavy interest burdens.
Healthy Gross And Operating MarginsRobust gross and operating margins reflect efficient manufacturing and a competitive cost structure in APIs and formulations. These margins provide a lasting buffer against pricing pressure, enabling reinvestment in product development and maintaining profitability over medium-term industry cycles.
Bears Say
Declining Net Profit MarginA falling net margin to 6.5% erodes retained earnings and weakens long-term capacity to fund growth internally. If structural (cost inflation, mix shift, pricing pressure), this trend can compress shareholder returns and require either efficiency gains or higher sales growth to restore prior profitability levels.
Negative Free Cash FlowNegative free cash flow signals that capex or working capital needs currently outstrip cash generated from operations. This constrains dividends, debt reduction, and strategic investments unless cash conversion improves; it's a durable liquidity risk if capital intensity or receivables remain elevated.
Earnings ContractionA substantial EPS decline indicates earnings pressure beyond revenue trends, suggesting margin squeeze or one-off costs. Persistent EPS contraction undermines return on equity and investor confidence, and requires structural fixes (cost control, product mix improvement) to restore sustainable earnings growth.
Morepen Laboratories Limited News
MOREPENLAB FAQ
What was Morepen Laboratories Limited’s price range in the past 12 months?
Morepen Laboratories Limited lowest stock price was ₹33.42 and its highest was ₹70.40 in the past 12 months.
What is Morepen Laboratories Limited’s market cap?
Morepen Laboratories Limited’s market cap is ₹22.86B.
When is Morepen Laboratories Limited’s upcoming earnings report date?
Morepen Laboratories Limited’s upcoming earnings report date is May 06, 2026 which is in 8 days.
How were Morepen Laboratories Limited’s earnings last quarter?
Morepen Laboratories Limited released its earnings results on Feb 10, 2026. The company reported ₹0.502 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.502.
Is Morepen Laboratories Limited overvalued?
According to Wall Street analysts Morepen Laboratories Limited’s price is currently Overvalued.
Does Morepen Laboratories Limited pay dividends?
Morepen Laboratories Limited pays a Annually dividend of ₹0.2 which represents an annual dividend yield of 0.49%. See more information on Morepen Laboratories Limited dividends here
What is Morepen Laboratories Limited’s EPS estimate?
Morepen Laboratories Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Morepen Laboratories Limited have?
Morepen Laboratories Limited has 547,953,700 shares outstanding.
What happened to Morepen Laboratories Limited’s price movement after its last earnings report?
Morepen Laboratories Limited reported an EPS of ₹0.502 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 1.24%.
Which hedge fund is a major shareholder of Morepen Laboratories Limited?
Currently, no hedge funds are holding shares in IN:MOREPENLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Morepen Laboratories Limited
Morepen Laboratories Limited develops, manufactures, markets, and sells active pharmaceutical ingredients (APIs), branded and generic formulations, and home health products in India. The company offers APIs for anti-histaminic, anti-asthmatic, anti-hypercholesterolemic, anti-hypertensive, and anti-diabetic drugs; point of care and medical devices; and home diagnostic products, such as air purifiers, thermometers, stethoscopes, blood pressure monitors, pulse-oximeters, nebulizers, glucometers, strips, sanitizers, disinfectant solutions, masks and gloves, and others. It also provides Burnol, a burn cream; Lemolate for cough and cold; and Fiber-X, a sat isabgol; and formulations for gastro, antibiotics, vitamins, nutritional, and anti-diabetics, as well as cardiac. In addition, the company is involved in the product contract manufacturing and brand sharing businesses; and provision of over-the-counter products under the Dr. Morepen brand. It exports its products to approximately 75 countries. Morepen Laboratories Limited was incorporated in 1984 and is based in New Delhi, India.
Technical Analysis
Gufic Biosciences Limited
―
Medi Assist Healthcare Services Limited
―
Panacea Biotec Limited
―
RPG Life Sciences Limited
―
Unichem Laboratories Limited
―